VAX-31
- Generic Name
- VAX-31
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
Phase 1
Active, not recruiting
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 20 valent pneumococcal conjugate vaccine
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 1015
- Registration Number
- NCT06151288
- Locations
- 🇺🇸
Coastal Carolina Research, North Charleston, South Carolina, United States
🇺🇸DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸WR-CRCN, Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath